Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 433 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epidermal Growth Factor Receptor Clear all
Active, not recruiting Phase 3 Interventional Results available

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496
View directory record Official record
Conditions
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions
Fulvestrant, Capivasertib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
818 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Recruiting Phase 1 Interventional

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

NCT04872166
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Breast Cancer
Interventions
BTX-A51
Drug
Lead sponsor
Edgewood Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 22, 2026, 10:47 PM EDT
Withdrawn Phase 2 Interventional

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

NCT02355431
View directory record Official record
Conditions
Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)
Interventions
Itacitinib, erlotinib, placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Ogden, Utah
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Sep 22, 2026, 10:47 PM EDT
Completed Phase 3 Interventional

Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer

NCT00362986
View directory record Official record
Conditions
Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunscreen, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
208
States / cities
Jacksonville, Florida • Aurora, Illinois • Bloomington, Illinois + 130 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 22, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

NCT00294762
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tarceva, carboplatin, paclitaxel
Drug
Lead sponsor
OSI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
38
States / cities
Alhambra, California • Bakersfield, California • Concord, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 22, 2026, 10:47 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Recruiting Phase 3 Interventional

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531
View directory record Official record
Conditions
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent), 5-fluorouracil (5-FU), Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Recruiting Not applicable Interventional

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

NCT06106477
View directory record Official record
Conditions
Breast Cancer
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Completed Phase 2 Interventional

Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy

NCT00004865
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, fluorouracil, paclitaxel
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Camden, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 8, 2009 · Synced Sep 22, 2026, 10:47 PM EDT
Terminated Phase 3 Interventional Results available

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

NCT00272987
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, paclitaxel, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
14
States / cities
Roswell, Georgia • Joliet, Illinois • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 22, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

NCT00588445
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer, Bronchioloalveolar Cancer
Interventions
Gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 22, 2026, 10:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of ZN-c5 in Subjects With Breast Cancer

NCT03560531
View directory record Official record
Conditions
Breast Cancer
Interventions
ZN-c5, Palbociclib
Drug
Lead sponsor
Zeno Alpha Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Tucson, Arizona • Los Angeles, California • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 22, 2026, 10:47 PM EDT
Not listed Phase 1Phase 2 Interventional

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

NCT05176665
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
Interventions
EMB-01
Drug
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Sep 22, 2026, 10:47 PM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions
FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

NCT02186301
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Rociletinib Mono-Therapy, Erlotinib Mono-Therapy
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
54
States / cities
Birmingham, Alabama • Burbank, California • Duarte, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 22, 2026, 10:47 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

NCT03778229
View directory record Official record
Conditions
Carcinoma
Interventions
osimertinib, savolitinib, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755
View directory record Official record
Conditions
Stage II-IIIB Non-small Cell Lung Carcinoma
Interventions
Osimertinib 80 mg/40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Santa Rosa, California • Las Vegas, Nevada • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
BNT326, Pumitamig
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Active, not recruiting Phase 1 Interventional

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

NCT05870579
View directory record Official record
Conditions
Breast Cancer
Interventions
[68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

NCT01783444
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Exemestane, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 22, 2026, 10:47 PM EDT
Active, not recruiting Phase 3 Interventional

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663
View directory record Official record
Conditions
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions
Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
40
States / cities
Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 22, 2026, 10:47 PM EDT
Completed No phase listed Observational

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

NCT04807595
View directory record Official record
Conditions
Breast Cancer
Interventions
None (Observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 22, 2026, 10:47 PM EDT